Group 1 - AIM ImmunoTech Inc. announced the closing of a public offering of 2,000,000 shares of common stock and accompanying warrants at a combined public offering price of $4.00 per share, resulting in gross proceeds of approximately $8.0 million before expenses [1][2][3] - The offering included Class E and Class F warrants, both of which are exercisable immediately upon issuance, with Class E warrants expiring on the fifth anniversary and Class F warrants expiring on the eighteen-month anniversary of the original issuance date [1] - Maxim Group LLC acted as the sole placement agent for this offering [2] Group 2 - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product is Ampligen® (rintatolimod), which is a first-in-class investigational drug with broad-spectrum activity in clinical trials [4]

Core Viewpoint - AIM ImmunoTech Inc. has announced a public offering of 2,000,000 shares of common stock and accompanying warrants, aiming to raise approximately $8.0 million before expenses [1]. Group 1: Offering Details - The public offering includes 2,000,000 shares of common stock or pre-funded warrants, along with Class E and Class F warrants, each allowing the purchase of up to 2,000,000 shares [1]. - The combined public offering price is set at $4.00 per share or $3.999 per pre-funded warrant, with warrants exercisable immediately upon issuance [1]. - Class E warrants will expire five years after issuance, while Class F warrants will expire eighteen months after issuance [1]. - The closing of the offering is expected around July 30, 2025, pending customary closing conditions [1]. Group 2: Financial and Regulatory Information - Gross proceeds from the offering are anticipated to be approximately $8.0 million before deducting placement agent fees and offering expenses [1]. - The offering is conducted under a registration statement on Form S-1, which was declared effective by the SEC on July 28, 2025 [3]. Group 3: Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [5]. - The company's lead product is Ampligen® (rintatolimod), a first-in-class investigational drug with broad-spectrum activity in clinical trials [5].

Market Performance - U.S. stocks traded mostly higher, with the Nasdaq Composite gaining over 50 points on Monday. The Dow increased by 0.07% to 44,932.70, the NASDAQ rose by 0.28% to 21,167.71, and the S&P 500 gained 0.09% to 6,394.33 [1] - Energy shares saw a rise of 0.9%, while materials stocks dipped by 1.1% on the same day [1] Commodity Prices - Oil prices increased by 2.2% to $66.57, while gold prices decreased by 0.9% to $3,306.90. Silver fell by 0.3% to $38.235, and copper dropped by 1% to $5.7285 [5] European Market Trends - European shares were lower, with the eurozone's STOXX 600 slipping by 0.19%. Spain's IBEX 35 Index fell by 0.09%, London's FTSE 100 decreased by 0.57%, Germany's DAX 40 declined by 0.89%, and France's CAC 40 fell by 0.37% [6] Asian Market Trends - Asian markets closed mixed, with Japan's Nikkei 225 falling by 1.10%, Hong Kong's Hang Seng gaining by 0.68%, China's Shanghai Composite rising by 0.12%, and India's BSE Sensex decreasing by 0.70% [7] Company-Specific Movements - CEA Industries Inc. saw its shares surge by 600% to $62.10 following a $500 million private placement announcement [9] - Celcuity Inc. shares increased by 167% to $36.80 after releasing topline results from its Phase 3 VIKTORIA-1 trial [9] - AIM ImmunoTech Inc. shares rose by 41% to $11.82 after announcing mid-year data from its Phase 2 DURIPANC trial [9] - Quhuo Limited shares dropped by 84% to $0.21 after announcing a strategic partnership with NIU World [9] - Adaptimmune Therapeutics plc shares fell by 63% to $0.1271 after agreeing to sell assets related to its cell therapy products for $55 million [9] - Sidus Space, Inc. shares decreased by 44% to $1.1200 following a $7.5 million public offering announcement [9]

Core Insights - Biotechnology firms are increasingly focusing on innovative combination therapies for difficult-to-treat cancers, generating significant investor interest, particularly in AIM ImmunoTech Inc. following a positive update from the DURIPANC Phase 2 study [1][5] Company Summary - AIM ImmunoTech is conducting the DURIPANC study, which evaluates Ampligen (rintatolimod) in combination with AstraZeneca's anti-PD-L1 inhibitor, Imfinzi, for metastatic pancreatic cancer patients who have stable disease after FOLFIRINOX treatment [2] - The DURIPANC study is a collaboration with AstraZeneca and Erasmus Medical Center, aiming to enroll up to 25 subjects in its Phase 2 portion [2] - As of the mid-year report, 14 subjects have been enrolled, with the primary objective being to determine the clinical benefit rate of the combination therapy [3] Study Results - The DURIPANC study has shown promising early signs of no significant toxicity, with 21% of patients experiencing progression-free survival (PFS) of over 6 months, and an additional 21% not yet progressed [4][6] - The overall survival (OS) rate for eligible patients is 64% over 6 months, which exceeds expectations for this treatment setting [6] - AIM has secured a U.S. patent for Ampligen as an oncology treatment in combination with an anti-PD-L1, extending protection until August 9, 2039 [4] Market Reaction - Following the positive mid-year report, AIM ImmunoTech shares increased by 36.79%, reaching $11.49 [5]

Core Insights - AIM ImmunoTech Inc. reported positive mid-year data from the Phase 2 DURIPANC study, indicating promising signs of no significant toxicity and superior progression-free survival (PFS) and overall survival (OS) in metastatic pancreatic cancer patients treated with Ampligen® and durvalumab [1][3][5] Company Overview - AIM ImmunoTech is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen® being its lead investigational drug [9] Study Details - The DURIPANC study is a collaboration with AstraZeneca and Erasmus Medical Center, aiming to evaluate the combination therapy of Ampligen and durvalumab in patients with stable disease post-FOLFIRINOX [1][4] - The study is expected to enroll up to 25 subjects, with 14 subjects enrolled as of the mid-year report [1] Preliminary Findings - The combination therapy has shown a well-tolerated safety profile, with approximately 21% of patients experiencing PFS greater than 6 months and 64% of eligible patients having OS greater than 6 months [5] - The study aims to assess clinical benefit rates, OS, PFS, and initiate immune-monitoring using tissue biopsies and immune profiling [1][2] Future Directions - Further analysis of immune-monitoring data is anticipated to provide insights into the biological activity and durability of response, as well as identify predictive biomarkers for patient selection [2][3] - The company has developed an intellectual property plan, including a U.S. patent for Ampligen as an oncology treatment, extending protection to August 9, 2039 [8]

Core Insights - AIM ImmunoTech Inc. presented its drug Ampligen at the U.S.-Poland Science and Technology Symposium 2025, highlighting its potential in immunotherapy [1][2] - Dr. Pawel Kalinski emphasized the importance of public-private partnerships in advancing cancer research and treatment development [2][4] - The conference focused on "Opportunities in Singularity," showcasing collaboration between various institutions and organizations [3] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19 [5] - Ampligen, the company's lead product, is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist with broad-spectrum activity in clinical trials [5] Future Initiatives - The CEO of AIM stated the goal of establishing clinical partnerships and licensing agreements in Europe, particularly in Poland, to enhance cancer research [4]

Core Viewpoint - AIM ImmunoTech Inc. has received a warning from NYSE American regarding non-compliance with minimum stockholders' equity requirements, with a deadline to regain compliance by June 11, 2026 [2][3]. Group 1: Compliance Issues - As of March 31, 2025, AIM reported a stockholders' deficit of negative $3.9 million, failing to meet the required equity of $4.0 million due to losses in three of the last four fiscal years [2][3]. - The NYSE American had previously issued a warning on December 17, 2024, and the current notification indicates that the deficiency remains unresolved [3]. - AIM has submitted a plan to regain compliance, which has been accepted by NYSE American, allowing until June 11, 2026, to rectify the situation [3]. Group 2: Trading Status - AIM's common stock resumed trading on NYSE American under the symbol "AIM" on June 17, 2025, and the warning does not affect trading or the company's business operations [4]. Group 3: Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its lead product being Ampligen (rintatolimod) [5].

Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product is Ampligen (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad spectrum activity in clinical trials [2] Trading Information - AIM ImmunoTech Inc.'s common stock has resumed trading on the NYSE American under the ticker symbol "AIM" effective June 17, 2025 [1]

Ampligen Program & Pipeline - Ampligen, an immuno-modulator, is the lead program with broad-spectrum activity demonstrated in human clinical studies[7] - The company is advancing a broad pipeline across multiple indications including Immuno-Oncology, Immune Disorders, and Viral Diseases[9] - The company plans to conduct a Phase 1/2 or Phase 2 study in collaboration with the University of Alabama-Birmingham, focusing on influenza, including avian influenza (Bird Flu)[10] Oncology Programs - The company is targeting multiple cancers with high unmet needs through immuno-therapy oncology programs[18] - In an Early Access Program for late-stage pancreatic cancer, the median overall survival (OS) was 19 months in the Ampligen cohort compared to 12 months for a well-matched historical control group[29] - The 19 months OS in Ampligen cohort represents 79 month increase survival benefit compared to current standard of care[29] - The company is enrolling and dosing patients in a Phase 2 study (DURIPANC) for Metastatic Pancreatic Ductal Adenocarcinoma, using Ampligen in combination with durvalumab[27] - Additional target oncology indications include Ovarian Cancer (19880 new cases annually), Breast Cancer (287850 new cases annually), Colorectal Cancer (151030 new cases annually), and Melanoma (99780 new cases annually)[26] Post-COVID Conditions - The company is exploring Ampligen as a potential treatment for Post-COVID Conditions, particularly fatigue, with a follow-up clinical trial planned[37] - Preliminary data from a study at the Hunter-Hopkins center showed improvements in exercise ability, overall fatigue levels, and post-exertional malaise in 4 patients treated for Long-COVID[38] - Final clinical study results on AMP-518 indicate that Ampligen improves measures of fatigue over placebo[42] Intellectual Property & Exclusivity - Ampligen has Orphan Drug Designation from the FDA and EMA, providing 7 years and 10 years of market exclusivity following approval, respectively[54] - The company has 46 patents worldwide and 72 pending applications[54]

Core Viewpoint - AIM ImmunoTech Inc. has secured a significant patent for the manufacturing of its drug Ampligen, extending patent protection until 2041, which enhances its control over the drug's synthesis and use in various therapeutic applications [1][2][3]. Patent Protection - The newly granted U.S. patent No. 12312376 covers methods for manufacturing a range of therapeutic double-stranded RNA products, including Ampligen, thereby strengthening AIM's intellectual property portfolio [1][2]. - AIM's overall patent portfolio includes protections for Ampligen in treating various conditions, with specific patents expiring between 2039 and 2042 [4]. Development and FDA Approval - The patent extension provides AIM with additional time to develop its drug program and pursue FDA approval for Ampligen across multiple indications, including cancers and viral diseases [3][5]. - AIM's intellectual property also includes multiple Orphan Drug Designations from the FDA and EMA, granting market exclusivity for seven to ten years post-approval for various conditions [5]. Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for cancers, immune disorders, and viral diseases, with Ampligen being its lead investigational drug, demonstrating broad-spectrum activity in clinical trials [6].